Welcome to our dedicated page for LABCORP HOLDINGS SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026. She was granted 3,300 non-qualified stock options with a $284.5 exercise price under the 2025 Omnibus Incentive Plan, vesting in three equal annual installments starting on that grant date.
She was also granted 1,100 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. After this grant, she directly holds 3,300 stock options and 3,230 Restricted Stock Units.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, received new equity awards. On February 10, 2026 he was granted 6,100 non-qualified stock options with an exercise price of $284.5 per share, vesting in three equal annual installments beginning February 10, 2027.
He was also granted 2,020 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments starting February 10, 2027. After this grant, he holds 6,100 options and 4,910 RSUs directly.
Labcorp Holdings Inc. director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, Kong acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock. These units vest fully on February 10, 2027.
Following this grant, Kong beneficially owns 1,670 Restricted Stock Units, held directly. This filing reflects a stock-based compensation award rather than an open-market purchase or sale.
Labcorp Holdings Inc. director Paul Rothman reported an equity award in the form of Restricted Stock Units. On February 10, 2026, he acquired 733 Restricted Stock Units as a grant, each representing the right to receive one share of Labcorp common stock if vesting conditions are met.
These Restricted Stock Units vest fully on February 10, 2027. Following this grant, Rothman beneficially holds a total of 1,670 Restricted Stock Units in a direct ownership capacity, aligning his compensation more closely with the company’s future share performance.
Labcorp Holdings Inc. director John H. Sampson received an equity award of 773 restricted stock units on February 10, 2026. The Form 4 reports this as an acquisition of derivative securities at a price of $0 per unit, held as direct beneficial ownership.
Each restricted stock unit represents the contingent right to receive one share of Labcorp common stock. The 773 restricted stock units vest fully on February 10, 2027, and the filing shows 773 derivative securities beneficially owned following the reported transaction.
Labcorp Holdings Inc. director Kathryn E. Wengel received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported at a price of $0 per unit as a grant, not an open-market purchase.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp common stock, and the units vest fully on February 10, 2027. Following this grant, Wengel beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Richelle P. Parham received a new equity award in the form of restricted stock units. On February 10, 2026, she acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock, at no cash cost.
The Restricted Stock Units vest fully on February 10, 2027, meaning the shares will be delivered if the vesting conditions are satisfied. After this grant, Parham beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Peter M. Neupert reported an equity award under a company plan. On February 10, 2026, he received 773 Restricted Stock Units (RSUs) at a price of $0 per unit. Each RSU represents the right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning he will receive the underlying shares if vesting conditions are met. After this grant, Neupert beneficially owns 1,670 RSUs in total, all held as direct ownership.
Labcorp Holdings Inc. director Kirsten M. Kliphouse acquired 773 Restricted Stock Units on February 10, 2026 as an equity grant. Each unit represents the right to receive one share of Labcorp common stock. These units vest in full on February 10, 2027, subject to the award terms.
Following this grant, Kliphouse beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership. The transaction was reported as a grant, award, or other acquisition at a price of $0 per unit.
Labcorp Holdings Inc. director Jeffrey A. Davis received an equity grant of 773 Restricted Stock Units on February 10, 2026. Each unit represents the right to receive one share of Labcorp common stock. The Restricted Stock Units vest fully on February 10, 2027.
After this award, Davis beneficially owns a total of 1,670 Restricted Stock Units in Labcorp through direct ownership, reflecting his aggregate RSU holdings as reported.